Tvardi Therapeutics, Inc.TVRDEarnings & Financial Report
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative targeted small molecule therapies for patients with hard-to-treat cancers and fibrotic diseases. Its lead development candidate targets the STAT3 signaling pathway, with ongoing programs addressing multiple high unmet medical needs across global patient segments.
TVRD Q4 FY2023 Key Financial Metrics
Revenue
$3.0M
Gross Profit
N/A
Operating Profit
$-32.6M
Net Profit
$-32.3M
Gross Margin
N/A
Operating Margin
-1085.5%
Net Margin
-1076.5%
YoY Growth
-7.9%
EPS
$-24.67
Tvardi Therapeutics, Inc. Q4 FY2023 Financial Summary
Tvardi Therapeutics, Inc. reported revenue of $3.0M (down 7.9% YoY) for Q4 FY2023, with a net profit of $-32.3M (down 6.6% YoY) (-1076.5% margin).
Key Financial Metrics
| Total Revenue | $3.0M |
|---|---|
| Net Profit | $-32.3M |
| Gross Margin | N/A |
| Operating Margin | -1085.5% |
| Report Period | Q4 FY2023 |
Revenue Breakdown
Tvardi Therapeutics, Inc. Q4 FY2023 revenue of $3.0M breaks down across 2 segments, led by Collaborative Revenue at $2.3M (76.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Collaborative Revenue | $2.3M | 76.7% |
| Other | $699.0K | 23.3% |
Tvardi Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Tvardi Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Collaborative Revenue and Other) has evolved quarter over quarter.
| Segment | Q4 FY2023 | Q3 FY2023 | Q2 FY2023 | Q1 FY2023 |
|---|---|---|---|---|
| Collaborative Revenue | $2.3M | $2.5M | $5.4M | — |
| Other | $699.0K | $946.0K | — | $3.0M |
Tvardi Therapeutics, Inc. Annual Revenue by Year
Tvardi Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $21.0M).
Tvardi Therapeutics, Inc. Quarterly Revenue & Net Profit History
Tvardi Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2023 | $3.0M | -7.9% | $-32.3M | -1076.5% |
| Q3 FY2023 | $4.9M | -55.0% | $-28.0M | -576.1% |
| Q2 FY2023 | $6.9M | -69.9% | $-31.5M | -454.0% |
| Q1 FY2023 | $6.2M | +28.7% | $-26.7M | -432.5% |
| Q4 FY2022 | $3.3M | +297.2% | $-30.3M | -930.4% |
| Q3 FY2022 | $10.8M | -46.7% | $-23.2M | -214.4% |
| Q2 FY2022 | $23.0M | — | $-4.2M | -18.3% |
| Q1 FY2022 | $4.8M | +147.5% | $-27.7M | -579.3% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.8M | $23.0M | $10.8M | $3.3M | $6.2M | $6.9M | $4.9M | $3.0M |
| YoY Growth | 147.5% | N/A | -46.7% | 297.2% | 28.7% | -69.9% | -55.0% | -7.9% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $223.9M | $226.6M | $213.5M | $182.2M | $153.3M | $134.4M | $115.3M | $125.8M |
| Liabilities | $19.8M | $22.1M | $28.7M | $23.5M | $16.7M | $25.5M | $29.7M | $68.8M |
| Equity | $204.1M | $204.4M | $184.8M | $158.8M | $136.6M | $108.9M | $85.6M | $-62.1M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-25.5M | $-4.5M | $-25.2M | $-23.5M | $-34.6M | $-20.4M | $-19.6M | $-17.4M |